



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

88

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/687,528	10/13/2000	David M. Stern	0575/62096/JPW/JML	8939
7590	05/18/2004		EXAMINER	
John P. white Cooper & Dunham, LLP 1185 Avenue of the Americas New York, NY 10036			CHEN, SHIN LIN	
			ART UNIT	PAPER NUMBER
			1632	

DATE MAILED: 05/18/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/687,528	STERN ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Shin-Lin Chen	1632	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 19 August 2003.
- 2a) This action is **FINAL**.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 3-5 and 11-14 is/are pending in the application.
  - 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 3-5 and 11-14 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.
 

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All    b) Some \* c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
|  | 6) <input type="checkbox"/> Other: _____                                    |

### **DETAILED ACTION**

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8-19-03 has been entered.

Applicants' amendment filed 4-25-03 has been entered. Claims 6 and 9 have been canceled. Claim 3 has been amended. Claims 3-5 and 11-14 are pending and under consideration.

#### ***Claim Rejections - 35 USC § 112***

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claim 11 recites the limitation "the inhibitor" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 11 depends on claim 3 but there is no "inhibitor" recited in claim 3.

4. Claim 13 recites the limitation "the inhibitor" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 13 depends on claim 3 but there is no "inhibitor" recited in claim 3.

5. Claim 14 recites the limitation "the inhibitor" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 14 depends on claim 3 but there is no "inhibitor" recited in claim 3.

***Claim Rejections - 35 USC § 112***

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 3-5 and 11-14 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The claims are directed to a method for preventing exaggerated restenosis in a diabetic subject by administering to said subject, such as a human, a therapeutically effective amount of soluble receptor for advanced glycation endproducts (sRAGE) *in vivo*. Claim 5 specifies the subject has undergone an angioplasty procedure. Claims 11, 12 and 14 specify the administration route of the inhibitor, such as bolus injection, oral administration, i.v., i.p. etc., or via device, such as a stent or an angioplasty balloon. Claim 13 specifies the inhibitor is administered at a rate of about 2 ug/kg/hr to about 100 ug/kg/hr.

The specification discloses reduction of smooth muscle proliferation and migration in carotid artery by treating Fatty Zucker rat having carotid artery balloon injury with soluble RAGE (sRAGE) via intraperitoneal injection.

The claims encompass using numerous sRAGE derived from various organisms, such as humans, cows, horses, rats, mice, sheep, other mammals, fishes, insects etc., to prevent exaggerated restenosis in a diabetic subject *in vivo*. The specification fails to provide adequate guidance and evidence for how to prevent exaggerated restenosis in a diabetic subject by administering to said subject any sRAGE derived from various organisms *in vivo*. The specification also fails to provide detailed information for the structural feature of sRAGE that contributes to prevent exaggerated restenosis.

The sRAGE derived from various organisms have different amino acid sequences, for example, the cow, human and murine sRAGE protein sequences disclosed in the present application differ from each other (see specification, pages 14, 16, 18, SEQ ID Nos. 1, 3 and 5). It was known in the art that amino acid sequence of a protein determines its structural and functional properties, and predictability of which amino acids can be removed from a protein's sequence and still result in similar activity is extremely complex, and well outside the realm of routine experimentation, because accurate predictions of a protein's structure from mere sequence data are limited. Rudinger, 1976 (Peptide Hormones, Edited by Parsons, University Park Press, Baltimore, p. 1-7), points out that "The significance of particular amino acids and sequences for different aspects of biological activity cannot be predicted *a priori* but must be determined from case to case by painstaking experimental study" (e.g. p. 6). Kaye et al., 1990 (Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 6922-6926) teaches that "A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding" (e.g. Title). Skolnick et al., 2000 (Trends in Biotech, Vol. 18, p. 34-39) states "Sequence-based methods for function prediction are inadequate because of the multifunctional

nature of proteins. However, just knowing the structure of the protein is also insufficient for prediction of multiple functional sites. Structural descriptors for protein functional sites are crucial for unlocking the secrets in both the sequence and structural-genomics projects" (e.g. abstract). Skolnick further states that "Knowing a protein's structure does not necessarily tell you its function" and "Because proteins can have similar folds but different functions, determining the structure of a protein may or may not tell you something about its function" (e.g. p. 36, box 2). In view of the lack of detailed information regarding the structural and functional requirements of the sRAGE to prevent exaggerated restenosis, and the unpredictability of polypeptide function from mere amino acid sequence, it would be unpredictable whether any sRAGE would be able to prevent exaggerated restenosis in a diabetic subject *in vivo*.

Claim 4 specifies the subject is a human. The biological environments in different organisms differ from each other physically and physiologically. Even if the sRAGE can function to prevent exaggerated restenosis in animal model, the data from animal model can not be extrapolated into success in preventing exaggerated restenosis in human. Gura (Science, Vol. 278, p. 1041-1042, 1997) reports "The fundamental problem in drug discovery for cancer is that the (animal) model systems are not predictive at all" and "The animals apparently do not handle the drugs exactly the way the human body does. And attempts to use human cells in culture don't seem to be faring any better, partly because cell culture provides no information about whether a drug will make it to the tumor site" (e.g. p. 1041, first column). Similarly, the effect of sRAGE in an animal model, such as a mouse model, may not be the same as that in a human. In view of such, one skilled in the art at the time of the invention would not know how to use a sRAGE derived from various organisms to prevent exaggerated restenosis in a human.

Therefore, it is concluded that based upon the nature of the claimed invention, the state of the art, the unpredictability found in the art, the teaching and working examples provided, and the breadth of the claims that it would require one skilled in the art at the time of the invention undue experimentation to practice over the full scope of the invention claimed.

***Conclusion***

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shin-Lin Chen whose telephone number is (571) 272-0726. The examiner can normally be reached on Monday to Friday from 9:30 am to 6 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (571) 272-0804. The fax phone number for this group is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Shin-Lin Chen, Ph.D.



SHIN-LIN CHEN  
PRIMARY EXAMINER